<DOC>
	<DOCNO>NCT00069030</DOCNO>
	<brief_summary>This study test safety immune system response new HIV vaccine . The vaccine study make HIV DNA produce laboratory . Only part virus 's DNA use vaccine vaccine cause HIV infection AIDS . In addition HIV DNA , vaccine contains interleukin-2 ( IL-2 ) DNA fuse portion immunoglobulin ( Ig ) DNA . IL-2 chemical stimulates immune system may improve response vaccine . Study hypothesis : The IL-2/Ig plasmid well tolerated human .</brief_summary>
	<brief_title>Safety Immune Response HIV Vaccine ( VRC-HIVDNA009-00-VP ) Administered With Interleukin-2/Immunoglobulin ( IL-2/Ig ) DNA Adjuvant Uninfected Adults</brief_title>
	<detailed_description>Over 90 % 40 million people infected HIV live develop country little access antiretroviral medication . The worldwide HIV/AIDS epidemic control development safe effective vaccine prevent HIV infection . DNA vaccine inexpensive construct , readily produce large quantity , stable long periods time . The DNA vaccine study , VRC-HIVDNA009-00-VP ( Gag-Pol-Nef-multiclade Env ) , use multiple gene product increase breadth immune response across different HIV subtypes . The DNA plasmids VRC-HIVDNA009-00-VP code protein HIV subtypes A , B , C , together represent 90 % new HIV infection world . The study vaccine administer adjuvant . The adjuvant DNA plasmid encode interleukin 2 ( IL-2 ) fuse Fc portion IgG enhance stability . This IL-2/Ig adjuvant may augment immune system 's response vaccine . Participants study randomly assign receive either vaccine adjuvant , vaccine placebo , adjuvant placebo , placebo alone . All injection administer needle-free injection upper arm . Participants receive four vaccine : one first study visit Months 1 , 2 , 6 . Participants follow-up visit 2 day injection . Some participant may receive another injection follow-up visit . All study participant follow 18 month 16 20 study visit . Study visit last 1/2 2 hour include blood urine test physical exam . Participants also six HIV test course study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria HIV negative Willing receive HIV test result Good general health Acceptable method contraception female reproductive potential Hepatitis B surface antigen negative Antihepatitis C virus antibody ( antiHCV ) negative negative HCV PCR antiHCV positive Normal thyroid stimulate hormone ( TSH ) level Exclusion Criteria HIV vaccine placebos prior HIV vaccine trial Immunosuppressive medication within 168 day prior first study vaccine administration Blood product within 120 day prior first study vaccine administration Immunoglobulin within 60 day prior first study vaccine administration Live attenuate vaccine within 30 day prior first study vaccine administration Investigational research agent within 30 day prior first study vaccine administration Subunit kill vaccine within 14 day prior first study vaccine administration Current tuberculosis prophylaxis therapy Clinical depression pharmacological treatment within past 2 year Active syphilis Serious adverse reaction vaccine . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Unstable asthma Type 1 Type 2 Diabetes Mellitus Thyroid disease require treatment Serious angioedema within past 3 year Uncontrolled hypertension Bleeding disorder Malignancy unless surgically remove , opinion investigator , likely recur study period Seizure disorder require medication within past 3 year Asplenia Mental illness would interfere compliance protocol Other condition , judgement investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>Vaccines , DNA</keyword>
	<keyword>Dose-Response Relationship , Immunologic</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Plasmids</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Interleukin</keyword>
	<keyword>IL2</keyword>
	<keyword>Ig</keyword>
	<keyword>IL @ /Ig</keyword>
</DOC>